Current landscape of US Food and Drug Administration use of expedited regulatory approvals for colorectal cancer care. Read more about Current landscape of US Food and Drug Administration use of expedited regulatory approvals for colorectal cancer care.
Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum. Read more about Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.
The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B. Read more about The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B.
KarXT for schizophrenia-effectiveness and value: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council. Read more about KarXT for schizophrenia-effectiveness and value: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Read more about Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
Resmetirom for nonalcoholic steatohepatitis. Read more about Resmetirom for nonalcoholic steatohepatitis.
The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum. Read more about The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.
The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis. Read more about The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis.
The effectiveness and value of belimumab and voclosporin for lupus nephritis. Read more about The effectiveness and value of belimumab and voclosporin for lupus nephritis.
The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder. Read more about The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder.
